Search

Displaying results 121 - 130 of 1901 in total
  1. Drug

    Veligrotug

    go.drugbank.com/drugs/DB18976
    Approved

    [L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929] … Veligrotug is a humanized IgG1 monoclonal antibody that binds the insulin-like growth factor-1 receptor and blocks ligand-induced receptor autophosphorylation, interrupting IGF-1R signaling.

    Synonyms: Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human-Mus musculus monoclonal VRDN-001 γ1-chain), disulfide with human-Mus musculus monoclonal VRDN-001 κ-chain, dimer, Immunoglobulin G1-kappa, anti-[Homo sapiens IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221)], chimeric monoclonal antibody (gamma1 heavy chain chimeric (1-454) [VH (Mus musculus IGHV1S81Categories: Insulin-like Growth Factor-1 Receptor Inhibitor
  2. Drug

    MP-0250

    go.drugbank.com/drugs/DB17218
    Investigational

    Synonyms: Designed ankyrin repeat protein (MP0250)
  3. Drug

    PMC-403

    go.drugbank.com/drugs/DB18132
    Investigational

    PMC-403 is a novel Tie2-activating antibody being investigated for the treatment of systemic capillary leak syndrome.

    Synonyms: a fully human monoclonal antibody that binds and activates the Tie2 receptor
  4. Drug

    Pyridoxine

    go.drugbank.com/drugs/DB00165
    ApprovedInvestigationalNutraceuticalVet approved

    Pyridoxine is the 4-methanol form of vitamin B6, an important water-soluble vitamin that is naturally present in many foods. As its classification as a vitamin implies, Vitamin B6 (and pyridoxine) are essential nutrients required for nor...

    Mixtures: CR-FRAN JARABE, DICLOVITH-B-FRTProducts: VITAMIN B6 RATIO 40MG FTA
  5. Drug

    Metformin

    go.drugbank.com/drugs/DB00331
    ApprovedInvestigational

    [A36559] Metformin was first approved in Canada in 1972,[A36552] and received subsequent FDA approval in the US in 1995.[L12207]

    Mixtures: Nra-sitagliptin/metformin, Nra-sitagliptin/metforminProducts: METFORMIN RATIO 500MG FTA, METFORMIN RATIO 850MG FTA
  6. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    [L51114] On August 2, 2024, the FDA granted the accelerated approval of afamitresgene autoleucel, making it the first FDA-approved TCR gene therapy and the first gene therapy for the treatment of synovial … genetically modified autologous T cell immunotherapy product consisting of CD4 and CD8 positive T cells transduced with a self-inactivating lentiviral vector (LV) expressing an affinity-enhanced T cell receptor

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE
  7. Drug

    Cefuroxime

    go.drugbank.com/drugs/DB01112
    ApprovedInvestigational

    Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.

    International brands: Zinacef danmarkProducts: CEFUROX BASICS 250MG FTA, CEFUROX BASICS 500MG FTA
  8. Drug

    ALLO-715

    go.drugbank.com/drugs/DB18640
    Investigational

    ALLO-715 is an allogeneic chimeric antigen receptor T Cell therapy targeting B cell maturation antigen (BCMA).

    Synonyms: Allogenic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen (BCMA)
  9. Drug

    Phenoxymethylpenicillin

    go.drugbank.com/drugs/DB00417
    ApprovedInvestigationalVet approved

    Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpe...

    Products: PENICILLIN V RAT 1MEGA FTA
  10. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without

    Synonyms: Superagonist interleukin-15:interleukin-15 receptor alphasu/fc fusion complex alt-803Categories: Interleukin-15 Receptor Agonist